Senti Biosciences Holdings Net Profit Margin Growth & History (SNTI)
Senti Biosciences Holdings's net profit margin was −279,263.64% for fiscal 2025.
View full Senti Biosciences Holdings company overviewSenti Biosciences Holdings annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −279,263.64% | — |
| 2023 | 2023-12-31 | −3,592.42% | −1820.96 pp |
| 2022 | 2022-12-31 | −1,771.45% | +643.17 pp |
| 2021 | 2021-12-31 | −2,414.62% | — |
Senti Biosciences Holdings quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −75,000.00% | — |
| Q1 2026 | 2026-03-31 | −26,381.25% | — |
| Q4 2025 | 2025-12-31 | −65,759.09% | — |
| Q3 2023 | 2023-09-30 | −5,852.16% | −4754.53 pp |
| Q2 2023 | 2023-06-30 | −2,721.54% | −1678.94 pp |
| Q1 2023 | 2023-03-31 | −1,807.14% | −424.47 pp |
| Q3 2022 | 2022-09-30 | −1,097.63% | +134.12 pp |
| Q2 2022 | 2022-06-30 | −1,042.60% | +500.72 pp |
| Q1 2022 | 2022-03-31 | −1,382.67% | — |
| Q3 2021 | 2021-09-30 | −1,231.75% | — |
| Q2 2021 | 2021-06-30 | −1,543.32% | — |
Senti Biosciences Holdings net profit margin trends
Between the periods ended 2021-12-31 and 2025-12-31, Senti Biosciences Holdings's net profit margin decreased from −2,414.62% to −279,263.64%, a change of −276849.01 percentage points. The latest reported quarter, Q2 2026, shows −75,000.00%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Senti Biosciences Holdings source filings ↗